Gastric Neuroendocrine Tumor
Associated Genetic Biomarkers
NCI Definition: A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the stomach. 
Gastric neuroendocrine tumors most frequently harbor alterations in TP53, ARID1A, TSHR, SETD2, and RB1 .
ARID1fs, TSHR Mutation, TSHR D276E, TP53fs, and TP53 c.217-c.1178 Missense are the most common alterations in gastric neuroendocrine tumor .
Of the biomarker-directed therapies for gastric neuroendocrine tumor, 1 is FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting .
There are 7 clinical trials for gastric neuroendocrine tumor, of which 4 are open and 3 are completed or closed. Of the trials that contain gastric neuroendocrine tumor as an inclusion criterion, 2 are phase 1/phase 2 (1 open) and 5 are phase 2 (3 open).
SSTR2, SSTR1, and SSTR3 are the most frequent gene inclusion criteria for gastric neuroendocrine tumor clinical trials .
177lu-opsc001, pen-221, and abemaciclib are the most common interventions in gastric neuroendocrine tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.